News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Cipla has a robust governance model focused on sustainability
PEEK brings a new quality to dental care for patients
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Subscribe To Our Newsletter & Stay Updated
